[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

June 2015 | 60 pages | ID: C38F3929017EN
ResearchInChina

US$ 1,550.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Chinese pharmaceutical packaging market reached RMB72 billion, up 10.6% from a year earlier.

As a traditional form of pharmaceutical packaging bottle, pharmaceutical glass bottle took up a large proportion of the Chinese pharmaceutical packaging market in initial development stage of the packaging market. However, affected by negative factors like the substitution of new packaging materials (plastics and aluminum foil) and continuous decline in purchase prices of packaging materials quoted by pharmaceutical companies due to reform in medical system, China pharmaceutical glass packaging industry has developed sluggishly, with its market share standing at estimated 45% or so for the time being.

Due to low barrier to entry, China’s pharmaceutical glass industry has been large but not strong as a whole, with low and medium-end products struggling with huge overcapacity and high-end products relying on imports. At present, developed countries around the world all use level I waterproof neutral borosilicate glass, while China still mostly adopts low borosilicate glass, soda-lime glass and almost domestically unique “semi-neutral borosilicate pharmaceutical glass” (its chemical stability cannot meet neutral requirements; the heavy metal content in glass is not defined clearly; dimensions are not accurate).

The production of neutral borosilicate glass faces dual barriers of raw materials and tube-making technology, which have been still controlled by foreign companies so far, resulting in persistently high production costs and limited applications. In 2012, German Schott AG, a world well-known pharmaceutical glass company, together with Zhejiang Xinkang Pharmaceutical Glass Co., Ltd., announced to establish a joint venture that would engage in pharmaceutical packaging, an important sign marking localization of pharmaceutical glass. But, even for the joint venture, it has to buy glass tube produced by Schott abroad.

However, the defect of low borosilicate glass easily flaking causes safety risks to health of users, so it is imperative to promote neutral borosilicate glass. Market demand for neutral borosilicate glass pharmaceutical containers has been growing by more than 20% over the past two years. More and more pharmaceutical players started to use neutral borosilicate glass, especially for high value-added products. For example, Buchang Pharma employs neutral borosilicate glass packaging materials for all its Danhong Injections, and some innovative R&D-oriented pharmaceutical companies like Jiangsu Hengrui Medicine Co., Ltd. also adopt neutral borosilicate glass.

With years of development and competition, the Chinese pharmaceutical glass business market still finds a relatively low level of concentration, but competitively leading companies have emerged in some market segments, especially in prefilled syringe market.

There are only five companies that have obtained assemblages for prefilled syringes in China, i.e., foreign-funded BD and Gerresheimer and domestic Shandong Weigao Group Medical Polymer, Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd. and Shandong Pharmaceutical Glass Co., Ltd.

By virtue of first-mover advantage and developed marketing network, Shandong Weigao Group Medical Polymer sold about 85.85 million prefilled syringes in 2014, accounting for more than 50% of the market in China, followed by foreign brands such as BD and Gerresheimer with market share of about 25%, and Zibo Minkang Pharmaceutical and Shandong Pharmaceutical Glass (the remaining). In addition, Shandong Weigao Group Medical Polymer still plans to implement the 50-million prefilled syringes project, which is expected to further raise the company’s share in prefilled system market.

China Pharmaceutical Glass Packaging Industry Report, 2014-2017 highlights the followings:
  • Status quo, market size, import & export, downstream demand and development forecast of China pharmaceutical glass industry;
  • Status quo, competitive landscape and price of China prefilled syringe industry;
  • Operation, pharmaceutical glass business and development prospects of 4 global and 6 domestic pharmaceutical glass packaging companies.
1 OVERVIEW OF PHARMACEUTICAL GLASS PACKAGING MATERIALS

1.1 Definition and Classification
1.2 Industry Chain

2 DEVELOPMENT OF CHINA PHARMACEUTICAL GLASS INDUSTRY

2.1 Status Quo
2.2 Market Size
2.3 Competitive Landscape
2.4 Import & Export
2.5 Prefilled Injection System
  2.5.1 Definition and Classification
  2.5.2 Status Quo
  2.5.3 Competitive Landscape
  2.5.4 Price
2.6 Downstream Demand
  2.6.1 Vaccine
  2.6.2 Blood Product
  2.6.3 Insulin
  2.6.4 Heparin
  2.6.5 Interferon
  2.6.6 Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
2.7 Development Trend

3 MAJOR PHARMACEUTICAL GLASS COMPANIES

3.1 Becton, Dickinson and Company
  3.1.1 Profile
  3.1.2 Operation
  3.1.3 Revenue Structure
  3.1.4 Pharmaceutical Packaging Materials Business
  3.1.5 Business in China
3.2 Gerresheimer AG
  3.2.1 Profile
  3.2.2 Operation
  3.2.3 Revenue Structure
  3.2.4 Business in China
3.3 SCHOTT AG
  3.3.1 Profile
  3.3.2 Operation
  3.3.3 Pharmaceutical Packaging Materials Business
  3.3.4 Business in China
3.4 Nipro Medical Corporation
  3.4.1 Profile
  3.4.2 Operation
  3.4.3 Revenue Structure
  3.4.4 Pharmaceutical Packaging Materials Business
  3.4.5 Business in China
    3.4.5.1 ChengDuPingYuanNipro Pharmaceutical Packaging Co., Ltd.
    3.4.5.2 Jilin NiproJiaheng Pharmaceutical Packaging Co., Ltd.
    3.4.5.3 Anyang NiproChangda Pharmaceutical Packaging Co., Ltd.
3.5 Shandong Pharmaceutical Glass Co., Ltd
  3.5.1 Profile
  3.5.2 Operation
  3.5.3 Revenue Structure
  3.5.4 Gross Margin
  3.5.5 Development Prospects and Forecast
3.6 Shandong Weigao Group Medical Polymer Co., Ltd.
  3.6.1 Profile
  3.6.2 Operation
  3.6.3 Revenue Structure
  3.6.4 Gross Margin
  3.6.5 R&D and Investment
  3.6.6 Major Customers
  3.6.7 Pharmaceutical Packaging Materials Business
  3.6.8 Development Prospects and Forecast
3.7 Cangzhou Four Stars Glass Co., Ltd.
3.8 Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd.
3.9 Chongqing Zhengchuan Pharmaceutical Packaging Co., Ltd.
3.10 Linuo Glassworks Group

4 SUMMARY AND FORECAST

SELECTED CHARTS

Classification and Applications of Pharmaceutical Glass
New Pharmaceutical Glass Packaging and Application
Diagram of Pharmaceutical Glass Packaging Industry Chain
Market Size of China Pharmaceutical Packaging Industry, 2010-2014
Output of Human Powder Injection (Including Freeze-dried) and Injection in China, 2010-2014
Output of Large Volume Parenterals (LVPs) in China, 2010-2014
Revenue and YoY Growth of Veterinary Drug Industry in China, 2007-2014
Import and Export Volume of Glass Ampoule in China, 2011-2014
Import and Export Value of Glass Ampoule in China, 2011-2014
Average Import and Export Price of Glass Ampoule in China, 2011-2014
Materials for Prefilled Syringes
Classification of Prefilled Syringe and Structural Diagram
Prefilled Syringe Suppliers in China and Their Products
Major Prefilled Syringe Manufacturers and Their Capacity, 2014
Price of Some Prefilled Drugs in China, 2010-2014
Market Size of Pharmaceuticals Industry in China, 2011-2015
Lot Release Volume of EPI an Extra EPI in China, 2007-2014
Lot Release Volume of Blood Products in China by Product, 2008-2014
Market Size of Insulin Drugs in China, 2007-2014
Theoretical Capacity of Heparin Sodium API in China, 2008-2014
Market Size and YoY Growth of Heparin Preparations in China, 2007-2014
Market Size and Sales Volume of Recombinant Interferon in China, 2013-2019E
Market Size and Sales Volume of rhG-CSF in China, 2013-2019E
List of Primary Businesses of BD
Revenue and Operating Income of BD, FY2010-FY2014
Revenue Structure of BD by Business, FY2013-FY2014
Revenue Structure of BD by Region, FY2013-FY2014
BD’s Revenue Breakdown from Medical Business by Product, FY2011-FY2014
Revenue Structure of Gerresheimer by Consumption Market, 2014
Revenue and Operating Income of Gerresheimer, 2009-2014
Revenue Breakdown of Gerresheimer by Business, 2009-2014
Revenue Structure of Gerresheimer by Region, 2014
Revenue and Profit of SCHOTT, FY2013-FY2014
Revenue Breakdown of SCHOTT by Region, FY2013-FY2014
SCHOTT’s Subsidiaries in China
Revenue and Net Income of Nipro, FY2010-FY2014
Revenue Structure of Nipro by Business, FY2013-FY2014
Revenue Structure of Nipro by Region, FY2014
Nipro’s Revenue from Glass Products Business and % of Total Revenue, FY2012-FY2014
Nipro’s Key Subsidiaries in China and Their Businesses
List of Main Products of Shandong Pharmaceutical Glass
Revenue and Net Income of Shandong Pharmaceutical Glass, 2008-2015
Operating Revenue Breakdown of Shandong Pharmaceutical Glass by Product, 2008-2014
Operating Revenue Breakdown of Shandong Pharmaceutical Glass by Region, 2008-2014
Gross Margin of Shandong Pharmaceutical Glass by Product, 2008-2014
Revenue and Gross Margin of Shandong Pharmaceutical Glass, 2014-2017E
Variety of Products and Main Products of Shandong Weigao Group Medical Polymer
Revenue and Net Income of Shandong Weigao Group Medical Polymer, 2009-2014
Revenue Breakdown of Shandong Weigao Group Medical Polymer, 2013-2014
Main High Value-added Conventional Medical Consumables of Shandong Weigao Group Medical Polymer
Revenue Breakdown of Shandong Weigao Group Medical Polymer by Region, 2008-2014
Prefilled Syringe Output and Sales of Shandong Weigao Group Medical Polymer, 2011-2014
Market Size of Pharmaceutical Packaging Industry in China, 2014-2017E


More Publications